Jianfeng Group Lin2016 -029 (Announcement on Progress of Subsidiary's Foreign Investment)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2016-029
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Progress of Subsidiary's Foreign Investment
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Basic Information on Foreign Investment in 1.
On July 12, 2016 , Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a subsidiary of the Company, and Germany Gefu Pharmaceutical Co., Ltd. (hereinafter referred to as "Gefu Pharmaceutical"), Zhuhai Hengqin Deyunjia International Trade Co., Ltd. (hereinafter referred to: de Yunjia) signed the "Sino-foreign Joint Venture Contract" and jointly funded the establishment of a Sino-foreign joint venture in Jinhua City, Zhejiang Province, China, committed to building a pharmaceutical company for infants and children. The Chinese name of the joint venture company is: Zhejiang Jindel Baby Pharmaceutical Co., Ltd. The registered capital of the joint venture company is RMB 20 million, of which: Jianfeng Pharmaceutical contributed RMB 11 million in cash, Ge Fu Pharmaceutical contributed RMB 5 million in the evaluation of intellectual property rights of proprietary technology, and Deyunjia contributed RMB 4 million in cash.
For details, please refer to 2016 -Lin 2016-026 "Announcement on Foreign Investment of Subsidiaries" published by the company in the designated information disclosure media "shanghai securities news", "china securities journal" and the website of Shanghai Stock Exchange (www.sse.com.cn ) on July 13, 40.
Progress of 2. Foreign InvestmentAfter the signing of the Sino-Foreign Joint Venture Contract, the parties to the cooperation have applied to the relevant departments in accordance with relevant national laws, regulations and relevant government regulations and obtained the Approval Certificate for the People's Republic of China Foreign-invested Enterprises and the Business License.
The main registration items of the "Business License" are as follows:
Name: Zhejiang Jindel Baby Drug Co., Ltd.
Unified Social Credit Code: 91330700MA28E8DU4L
Type: Limited Liability Company (
Sino-foreign Joint Venture)
Domicile: legal Representative of, 3rd Floor, X02 Office Quality Inspection Building, No. 58
, Gaofan Section, Tangxi Town, Wucheng District, Jinhua City, Zhejiang Province: Jiang XiaomengRegistered Capital: RMB 20 Million Yuan
Date of Establishment: August 30, 2016
Business Term: 2016
from August 30 to August 29, 2046
Scope of business: drug research and development, drug production (see "Drug Production License" for the specific scope), drug business (see "Drug Business License" for the specific scope), import and export of health products. (For projects subject to approval according to law, business activities can only be carried out after approval by relevant departments)As of the date of this announcement, the cooperating parties have not yet made capital contributions.
3. Reference Document
Copy of Business License of Zhejiang Jindal Baby Pharmaceutical Co., Ltd. and Approval Certificate of the People's Republic of China Foreign Investment Enterprise.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
September 2, 2016
More information
On the afternoon of June 9, Peak Cable Company organized all employees to learn fire fighting knowledge and conducted fire fighting and emergency escape drills. Since June, the subordinate enterprises of the company have organized training, learning and drills related to production safety according to their own characteristics and combined with the actual work. Safety production month series of activities carried out in an orderly manner.
2022
06-13
Spike Postdoctoral Research Papers on International Frontier Journals
Recently, good news came from the postdoctoral workstation of Jianfeng Pharmaceutical. Under the guidance of workstation mentor Jiang Xiaomeng, associate researcher Yang Xiaoxiao has made new progress in the treatment of alcoholic liver disease. The relevant research results "Roxadustat, a hypoxia-inducible factor 1a activator, attenuates both long- and short-term alcohol induced alcoholic liver disease" were published in the internationally renowned academic journal "Frontiers in Pharmacology. This journal is a frontier journal in the field of international pharmacy, mainly publishing academic papers and information on basic and clinical pharmacology, medicinal chemistry, pharmacology and toxicology.
2022
06-01
Daye Peak QC Achievements Won the Third Prize of Huangshi City
On May 7, Huangshi City Quality Strong City Working Committee organized a 2022 QC Results Conference. The QC project of "Technical Transformation of Ore Limestone Batching System" of Daye Peak Cement Company won the third prize.
2022
06-01
On April 28, Dalian Commodity Exchange held an online working meeting to announce the results of the 2021 excellent delivery warehouse and delivery warehouse excellent futures personnel selection, peak international trading company won the 2021 "excellent designated delivery warehouse" title, futures commissioner Ruan Weihang won the "excellent futures personnel" title.
2022
06-01
Cranberry extract combination identification detection method won the invention patent
After cranberry extract products were included in the "Zhejiang Province Key High-tech Product Development Project Plan" in 2021, Jianfeng Health Technology Company recently obtained an invention patent for the identification and detection method of cranberry extract. This new combined identification and detection method developed by Jianfeng Health identifies whether catechin or procyanidin B2 is added in cranberry extract by thin layer analysis, and then detects the unique A- type procyanidin and its chromatographic distribution in cranberry extract by high performance liquid chromatography, so as to improve the accuracy of product judgment. The identification method has the characteristics of accurate results and short detection time, which is of great significance to standardize the cranberry extract market and promote the healthy development of the industry, and has been unanimously recognized by peers.
2022
05-20
Daye Peak Manufacturing Department Won the Title of "Worker Pioneer" in Hubei Province
A few days ago, the manufacturing department of Daye Peak Cement Company was awarded the title of "Worker Pioneer" by the Hubei Provincial Federation of Trade Unions. Daye Jianfeng Manufacturing Department not only continued to actively explore and achieved good results in energy saving and consumption reduction, technological transformation, product quality process control, and economic responsibility system to guide management, but also improved Daye Jianfeng's overall operation level and won Huangshi City The seventh "Mayor Quality Award" created conditions and was fully affirmed by government departments at all levels.
2022
05-20
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page